Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.70 |
| ▸ | PPARA | Q07869 | 13/20 | 0.70 |
| ▸ | PPARD | Q03181 | 9/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6002523 | 0.91 | PPARG (0.81) | PPARGPPARAPPARD | |
| SCHEMBL7244388 | 0.91 | PPARG (0.69) | PPARGPPARAPPARDP2RX4 | |
| SCHEMBL7928584 | 0.90 | PPARG (0.81) | PPARGPPARAPPARD | |
| SCHEMBL7517998 | 0.89 | PPARG (0.66) | PPARGPPARAPPARDP2RX4CACNA1H | |
| SCHEMBL5342984 | 0.83 | PPARA (0.83) | PPARGPPARAPPARD | |
| SCHEMBL4823006 | 0.83 | PPARA (0.83) | PPARGPPARAPPARD | |
| Ragaglitazar SCHEMBL29369224 | 0.82 | PPARA (1.00) | PPARGPPARAPPARD | |
| Ragaglitazar SCHEMBL682732 | 0.82 | PPARA (1.00) | PPARGPPARAPPARD | |
| Ragaglitazar SCHEMBL676872 | 0.82 | PPARA (1.00) | PPARGPPARAPPARD | |
| Ragaglitazar SCHEMBL4822459 | 0.82 | PPARA (1.00) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223881-B2 | Process for the preparation of new antidiabetic agents | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-05-29 | — | — | US | disclosed |
| US-20030125553-A1 | Process for the preparation of new antidiabetic agents | DR. REDDY'S LABORATORIES LIMITED | 2003-07-03 | — | — | US | disclosed |
| US-6531596-B1 | S(-)-2-methoxy-3-(4-(2-(phenoxazin-10-yl)methoxy) phenyl)propionic acid; benzylating p-hydroxybenzaldehyde or tyrosine; reaction with phenoxazinyl mesylate | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-03-11 | — | — | US | disclosed |
| EP-1124808-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF NEW ANTIDIABETIC AGENTS | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026200-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF NEW ANTIDIABETIC AGENTS | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125553-A1 | Process for the preparation of new antidiabetic agents | GLP1R, GPR119, SLC5A1 | PPARG 103/4885PPARA 108/4885PPARD 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.